Licensing and Commercialization Agreement with Novartis Pharma AG (Tables)

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of the components of the Company's collaboration revenue

Below is a summary of the components of the Company’s collaboration revenue for the three and six months ended June 30, 2017 and June 30, 2016:

	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
License revenue	$	—	$	22,937	$	—	$	22,937
Research and development activity revenue	1,658		5,150		3,316		6,425
API transfer revenue	—		102		—		14,545
Joint operating committee revenue	3		9		7		12
Total collaboration revenue	$	1,661	$	28,198	$	3,323	$	43,919